Information worth keeping on file if you need to throw figures at people.
Access the report at the URL and download a free sample
According to Hexa Research, the U.S. medical cannabis market is expected to reach $19.48 billion by 2024. The projected growth is largely driven by the medical benefits of cannabis. Symptoms and conditions that may be treated by cannabis include cancer, HIV, AIDS, Alzheimer’s disease, and multiple sclerosis. Chronic pain accounted for 46 percent of the U.S. cannabis medical market share in 2016. According to the research, the solid cannabis edibles in 2016, within the U.S. market generated $2.47 billion in revenue and are expected to continue to dominate the cannabis industry. California, the first state to legalize medical use for cannabis had the highest revenue in 2016 and is expected to grow at a CAGR of 13 percent to 2024. Pivot Pharmaceuticals Inc. (OTC: PVOTF), General Cannabis Corp. (OTC: CANN), Cara Therapeutics Inc. (NASDAQ: CARA), Aphria Inc. (OTC: APHQF), India Globalization Capital, Inc. (NYSE: IGC)